MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Apr 16, 2021

Editas Medicine (EDIT, $34.90) shares got a sell rating  from Goldman Sachs

Editas Medicine  shares got a sell rating  from Goldman Sachs as the latter initiated coverage on the stock.

Goldman Sachs analysts set a price target of $20 a share, a Wall Street low, on the biotech shares. According to the analysts, the risk-reward dynamic was skewed negatively for the company.

Goldman analyst Madhu Kumar mentioned in a note that initial results from Editas’ experimental Crispr gene editing product EDIT-11 in a rare eye disease may not lead to adequate productive editing to meaningfully improve patients' vision. Also affecting the rating is competition from ProQR Therapeutics for treatment of Leber's congenital amaurosis. 

On the other hand, Kumar was more optimistic on Apellis Pharmaceuticals   and Dicerna Pharmaceuticals. The analyst has price targets of $130  on Apellis and $48 on Dicerna – both Wall Street highs. Both got buy ratings.

 

Related Ticker: EDIT

EDIT's RSI Indicator ascending out of oversold territory

The RSI Indicator for EDIT moved out of oversold territory on November 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In of the 43 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

EDIT moved below its 50-day moving average on October 28, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on November 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EDIT entered a downward trend on November 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.727) is normal, around the industry mean (23.122). P/E Ratio (0.000) is within average values for comparable stocks, (61.014). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (4.733) is also within normal values, averaging (332.704).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.15B. The market cap for tickers in the group ranges from 58 to 110.5B. VRTX holds the highest valuation in this group at 110.5B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 66%. MRSN experienced the highest price growth at 210%, while KRRO experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 53%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was 443%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 57
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: 5 (-100 ... +100)
Related Portfolios: BIOTECHNOLOGY SECTOR
View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EDIT showed earnings on November 10, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interact to see
Advertisement
The Double Agent Trading Bot is engineered to adapt to market fluctuations, deploying two specialized agents to detect bullish and bearish signals.
#artificial_intelligence#trading
Bank of America Corporation (NYSE: BAC) remains a cornerstone of the U.S. financial sector, with its vast operations and significant market presence.
#artificial_intelligence#trading
On May 16, 2025, Moody's Ratings downgraded the United States' sovereign credit rating from its pristine AAA to Aa1, citing concerns over the nation's ballooning $36 trillion debt.
#trading
Tickeron, Inc., a leading provider of AI-driven trading tools, is thrilled to announce the launch of its token on the innovative Believe App, a platform revolutionizing community-driven funding.
#trading
Discover how AI-powered Dual Agent Trading Bots are transforming emotional trading into data-driven strategy. From mastering fear and greed to using inverse ETFs and pattern recognition, this article reveals how Tickeron's Agentic AI enables smarter, adaptive market moves.
#trading
Walmart’s stock is up nearly 54% in 2025, fueled by strong earnings, e-commerce growth, and investor confidence. This article explores Walmart’s financials, AI-driven analysis tools from Tickeron, and how traders are navigating market volatility with WMT.
#trading
Alphabet Inc. (GOOG, GOOGL), the parent company of Google, today released a financial update highlighting its performance and strategic initiatives as it approaches its Q2 2025 earnings report on July 29.
A routine Treasury bond auction shook markets on May 21, 2025, triggering an 80-point S&P 500 plunge as yields spiked above 5%. Explore what caused the sudden drop, how macroeconomic pressures played a role, and how Tickeron’s AI trading bots capitalized on the chaos.
#investment#trading
Ethereum ($ETH) is nearing a potential breakout above $4,000 as its 3-day chart forms a bullish Descending Broadening Wedge. With AI trading tools like Tickeron’s proven agents, traders are watching closely for a move that could define the next major crypto trend.
Bitcoin has officially hit $109,000 on May 21, 2025—exactly as predicted by Tickeron’s AI nearly two months ago. This milestone validates the platform’s AI accuracy and highlights how traders can use Tickeron’s AI Double Agents to navigate crypto market volatility with confidence.
Ethereum (ETH) is capturing the attention of traders and analysts alike, with its 3-day chart forming a Descending Broadening Wedge pattern—a classic technical setup that often precedes significant price movements.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading tools, shared a bold prediction on X.com about Bitcoin’s (BTC) price trajectory.
#artificial_intelligence#trading
A turbulent week rocked global markets as the S&P 500 slid 3% following a U.S. credit downgrade, while Bitcoin surged past $111K and gold soared. Strong UK inflation and retail sales data added to the volatility, highlighting growing concerns over global economic stability.
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#investment#artificial_intelligence
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#artificial_intelligence#trading
Tickeron, a leader in AI-powered financial solutions, proudly announces the launch of its Double Agent Trading Bot, designed for trading Carpenter Technology Corporation (CRS) and Direxion Daily Semiconductor Bear 3x Shares (SOXS).
#artificial_intelligence
Apple Inc. (AAPL), a global leader in consumer electronics, continues to be a cornerstone of the technology sector, driving innovation and commanding significant market attention.
#artificial_intelligence
NVIDIA’s earnings on May 28 could jolt the tech sector. With market volatility rising, traders are turning to Tickeron’s AI Agent for real-time insights, predictive analytics, and dual-strategy trading tools to navigate potential price swings and seize market opportunities.
#artificial_intelligence